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ARTICLE
Enhanced Response to Enzyme Replacement Therapy
in Pompe Disease after the Induction of Immune Tolerance
Baodong Sun, Andrew Bird, Sarah P. Young, Priya S. Kishnani, Y.-T. Chen, and Dwight D. Koeberl
Pompe disease, which results from mutations in the gene encoding the glycogen-degrading lysosomal enzyme acid a-
glucosidase (GAA) (also called “acid maltase”), causes death in early childhood related to glycogen accumulation in
striated muscle and an accompanying infantile-onset cardiomyopathy. The efficacy of enzyme replacement therapy (ERT)
with recombinant human GAA was demonstrated during clinical trials that prolonged subjects’ overall survival,prolonged
ventilator-free survival, and also improved cardiomyopathy, which led to broad-label approval by the U.S. Food and
Drug Administration. Patients who lack any residual GAA expression and are deemed negative for cross-reacting im-
munologic material (CRIM) have a poor response to ERT. We previously showed that gene therapy with an adeno-
associated virus (AAV) vector containing a liver-specific promoter elevated the GAA activity in plasma and prevented
anti-GAA antibody formation in immunocompetent GAA-knockout mice for 18 wk, predicting that liver-specific ex-
pression of human GAA with the AAV vector would induce immune tolerance and enhance the efficacy of ERT. In this
study, a very low number of AAV vector particles was administered before initiation of ERT, to prevent the antibody
response in GAA-knockout mice. A robust antibody response was provoked in naive GAA-knockout mice by 6 wk after
a challenge with human GAA and Freund’s adjuvant; in contrast, administration of the AAV vector before the GAA
challenge prevented the antibody response. Most compellingly, the antibody response was prevented by AAV vector
administration during the 12 wk of ERT, and the efficacy of ERT was thereby enhanced. Thus, AAV vector–mediated gene
therapy induced a tolerance to introduced GAA, and this strategy could enhance the efficacy of ERT in CRIM-negative
patients with Pompe disease and in patients with other lysosomal storage diseases.
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Infantile-onset Pompe disease (also known as “glycogen
storage disease II” [MIM 232300]) is associated with mus-
cle weakness, hypotonia, and lethal cardiomyopathy dur-
ing infancy, whereas late-onset Pompe disease features
progressive weakness without significant cardiomyopa-
thy.1,2 The histopathology of Pompe disease includes pro-
gressive lysosomal accumulation of glycogen in cardiac
and skeletal muscle. The in vivo efficacy of enzyme-
replacement therapy (ERT) for Pompe disease was dem-
onstrated first in acid a-glucosidase (GAA)–deficient Jap-
anese quail by both clinical and metabolic correction3 and
then later in the GAA-knockout (GAA-KO) mouse model,
by reducing the glycogen accumulation and restoring
the GAA activity in the heart and skeletal muscle.4,5 The
preclinical data justified an initial phase I/II clinical
trial.3,6 Further development of recombinant human GAA
(rhGAA) involved two pivotal clinical trials that differed
primarily in age at study entry. Study 1 enrolled subjects
aged !6 mo and demonstrated prolonged survival in re-
sponse to rhGAA therapy; furthermore, all 18 patients
were alive at age 18 mo, and 15 (83%) showed invasive
ventilator–free survival at age 18 mo.7 Study 2 enrolled
subjects aged 6–36 mo and demonstrated improved sur-
vival in response to ERT, although no difference in ven-
tilator dependence was realized. Both protocols improved
cardiomyopathy, growth, and motor development; how-
ever, the more-robust outcomes in study 1 emphasized the
value of early treatment in infantile-onset Pompe disease.
The main limitation of ERT in Pompe disease is a well-
recognized variability of response by skeletal muscle. Po-
tential factors involved in this variability include the ex-
tent of muscle damage at the start of ERT, the lower
number of mannose-6-phosphate receptors in skeletal
muscle in comparison with in the heart, the resistance to
correction by type II myofibers, and the formation of high-
titer antibodies in cross-reacting immunologic material
(CRIM)–negative patients.7–9
Animal and human studies have suggested that for-
mation of antibodies to rhGAA reduced the efficacy of ERT.
For instance, GAA-KO mice produced anti-GAA antibodies
in response to intravenously administered rhGAA and
died after subsequent injections.5 In the first pilot study
of ERT that used Chinese hamster ovary (CHO) cell–
derived rhGAA, both CRIM-negative subjects with Pom-
pe disease had markedly reduced efficacy of ERT in asso-
ciation with high-titer antibodies against human GAA
(hGAA).6 Phase II and III studies revealed that patients
with the highest sustained titers of antibody had the least
favorable outcome.7,9 The similarity with regard to the an-
tibody response in GAA-KO mice and in CRIM-negative
patients with Pompe disease could be linked to the lack
of residual GAA protein expression.
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Intravenous administration of adenovirus vectors en-
coding GAA transiently corrected the glycogen storage in
the striated muscle of GAA-KO mice,10,11 although glyco-
gen gradually reaccumulated coincident with the forma-
tion of anti-GAA antibodies.12 Even when GAA-KO mice
were rendered immunotolerant to hGAA by neonatal ad-
ministration of the recombinant enzyme, only a subset of
those mice failed to produce anti-GAA antibodies in re-
sponse to administration of an adeno-associated virus
(AAV) vector encoding hGAA.13 In marked contrast, ad-
ministration of an AAV vector containing a liver-specific
promoter showed evasion of immune responses to in-
troduced hGAA in response to only 1010 vector particles
and achieved near-total clearance of accumulated glyco-
gen from skeletal muscle with a 10-fold higher vector
quantity.14,15
Liver-specific expression has accomplished immune tol-
erance to therapeutic proteins in several models of genetic
diseases that result from a null mutation, including mice
with Pompe disease. Immune tolerance was established
through high-level liver-specific expression, as demon-
strated through dose-reduction experiments in mice with
hemophilia B (MIM 306900).16 Furthermore, the use of a
muscle-specific promoter failed to prevent antibody re-
sponses to the therapeutic protein in mice with either
hemophilia B or Pompe disease.17,18 A unique liver-specific
promoter derived from the thyroid hormone–binding
globulin promoter sequence (denoted “LSP”) prevented
the antibody response against factor IX and against GAA
in immunocompetent mice,14,19 and its activity was highly
restricted to the liver as compared with muscle.14 The rel-
evance of liver-specific expression in response to therapy
in lysosomal storage disorders was further emphasized by
the ability of a different liver-specific promoter to prevent
the formation of antibodies against a-galactosidase in
mice with Fabry disease (MIM 301500).20,21 The mecha-
nism for achieving immune tolerance, although incom-
pletely understood, clearly depends on the induction of
regulatory T cells that repress the formation of cytotoxic
T cells.16,21,22 The LSP reduced the g-interferon response to
introduced GAA expression in comparison with a univer-
sally active promoter, which is consistent with abrogation
of the cytotoxic T-cell responses.14 Thus, GAA expression
with a liver-specific promoter could potentially prevent
both humoral and cellular immune responses to intro-
duced GAA, thereby enhancing the response to therapy
in Pompe disease.
The potential role for gene therapy as an immunomo-
dulatory agent in CRIM-negative infantile Pompe disease
has become evident. Therefore, we evaluated the hypoth-
esis that immune tolerance to hGAA could be achieved
by administration of a subtherapeutic dose of the AAV
vector containing the LSP in GAA-KO mice. End points
included motor performance, avoidance of antibody re-
sponses, and biochemical correction. Immune tolerance
to hGAA was evaluated through antibody levels in re-
sponse to an immune challenge in vector or mock-treated
GAA-KO mice. The concept of AAV vector–mediated im-
munomodulatory gene therapy can thus be advanced in
CRIM-negative infantile Pompe disease.
Methods
Preparation of AAV Vector
In brief, 293 cells were transfected with the pAAV-LSPhGAApA
vector plasmid,14 the AAV packaging plasmid p5E18-VD 2/8 (cour-
tesy of Dr. James M. Wilson, University of Pennsylvania, Phila-
delphia),23 and pAdHelper (Stratagene). Cell lysate was harvested
48 h after infection, was freeze-thawed three times, and was iso-
lated by sucrose-cushion pelleting followed by two cesium
chloride–gradient centrifugation steps. AAV stocks were dialyzed
against three changes of Hanks buffer, and aliquots were stored
at 80C. The number of vector DNA containing–particles was
determined by DNase I digestion, DNA extraction, and Southern-
blot analysis. All viral vector stocks were handled in accordance
with Biohazard Safety Level 2 guidelines published by the Na-
tional Institutes of Health (NIH).
The LSP in pAAV-LSPhGAApA was subcloned from pAAV-LSP-
cFIX (courtesy of Dr. Inder Verma, Salk Institute, La Jolla, CA;
sequence is available on request). This LSP24 contains a thyroid
hormone–binding globulin (thyroxine-binding globulin of serum
[MIM 188600]) promoter sequence (475 through 4)25 down-
stream from two copies of an a1-microglobulin/bikuninprecursor
(MIM 176870) enhancer sequence (2804 through 2704).26
In Vivo Analysis of AAV Vector
The AAV type 8 pseudotyped (AAV2/8) vector stocks were ad-
ministered intravenously (via the retro-orbital sinus) in 3-mo-old
GAA-KO mice.27 At the indicated postinjection time points,
plasma or tissue samples were obtained and were processed as
described in the following two paragraphs. All animal procedures
were done in accordance with guidelines approved by the Duke
University Institutional Animal Care and Use Committee.
Rotarod testing was performed as described elsewhere.28 GAA
activity and glycogen content were analyzed as described else-
where.10 A P value !.05 indicated a statistically significant differ-
ence between the observed values for each group of GAA-KO mice
after AAV vector administration and for the control group of PBS-
injected GAA-KO mice.
Western blotting of hGAA was performed as described else-
where,28 by use of the hGAA monoclonal antibody (courtesy of
Genzyme), lysosomal-associated membrane protein 2 (LAMP-2)
rabbit polyclonal antibody (Abcam), and glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) rabbit polyclonal antibody (Ab-
cam). ELISA was performed as described elsewhere.29 All samples
yielded absorbance values that were within the linear range of
the assay at this dilution.
ERT in GAA-KO Mice
ERT was modeled in GAA-KO mice by retro-orbital injection of
rhGAA (5 mg/ml [supplied by Genzyme]) over ∼15 s at either 20
mg/kg or 100 mg/kg. When high-dose rhGAA (100 mg/kg) was
administered, pretreatment with diphenhydramine (5 mg/kg) by
intraperitoneal injection preceded rhGAA administration by 10
min.
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Figure 1. ELISA for anti-hGAA IgG in GAA-KO mice after AAV2/
8 vector administration. Mice were administered the AAV vector
(AAV), followed by ERT ( ) or no ERT ( except at agenp 6 np 6
7.5 mo, when ), PBS without ERT (PBS, ), or immunenp 4 np 5
challenge with rhGAA  Freund’s adjuvant at age 4.5 mo after
AAV vector administration (AAV, ) or mock treatment (PBS,np 6
). A, Absorbance for 1:200 dilution of plasma from the in-np 7
dicated groups of mice after hGAA  Freund’s adjuvant challenge
or ERT. The mean and SD are shown. B, Titer of anti-GAA IgG 12
wk after hGAA  Freund’s adjuvant challenge. Each bar (mn) rep-
resents a single mouse. Absorbance values were deemed positive
if 10.2. The P value was calculated with a two-tailed homoscedastic
Student’s t test.
Results
The potential role of immune tolerance in mediating the
response to ERT among CRIM-negative subjects with
Pompe disease was evaluated in GAA-KO mice. A low, sub-
therapeutic number of AAV2/8 vector14 particles was ad-
ministered to 3-mo-old GAA-KO mice, at 6 wk before an
immune challenge with rhGAA. Naive, PBS-treated mice
served as mock-treated controls. An immune challenge
consisting of rhGAA (20 mg/kg, the standard dose for
humans7,9) was administered with modified Freund’s ad-
juvant by intraperitoneal injection at age 4.5 mo to vector-
treated and mock-treated GAA-KO mice. Anti-hGAA an-
tibodies were detected only in the mock-treated GAA-KO
mice at ages 6 mo and 7.5 mo (absorbance 10.2) (fig. 1A).
The titer for mock-treated GAA-KO mice was significantly
elevated at age 6 mo, in comparison with AAV vector–
treated GAA-KO mice ( ) (fig. 1B). The absence ofPp .007
significant anti-hGAA antibodies suggested immune tol-
erance to hGAA after AAV2/8 vector administration, in
support of the hypothesis that gene therapy could fulfill
an immunomodulatory role in CRIM-negative infantile
Pompe disease.
The effect of pre-existing immunity was evaluated in
GAA-KO mice after immune challenge. High-dose rhGAA
(100 mg/kg) was administered once at age 9 mo, after
immune challenge with rhGAA and Freund’s adjuvant at
age 4.5 mo, to seropositive mock-treated GAA-KO mice,
to seronegative vector-treated GAA-KO mice, and to naive
GAA-KO mice that had not received rhGAA previously.
This enzyme-replacement regimen has reduced glycogen
accumulation in the heart but not skeletal muscle of GAA-
KO mice within 3 wk after treatment (authors’ unpub-
lished data). Endurance was significantly improved only
for vector-treated mice, indicating that seropositivity pre-
vented efficacy of ERT (fig. 2A). Biochemical correction
was demonstrated only for seronegative vector-treated
GAA-KO mice. GAA activity was significantly elevated in
the heart for seronegative GAA-KO mice, in comparison
with seropositive GAA-KO mice (fig. 2B). Glycogen con-
tent was similarly reduced in the heart for seronegative
GAA-KO mice (fig. 2C). Partial biochemical correction was
observed in the diaphragm of vector-treated or naive GAA-
KO mice (fig. 2B and 2C).
Western blotting detected higher levels of hGAA in the
heart of seronegative and naive GAA-KO mice, in com-
parison with seropositive mice; therefore, the presence of
anti-GAA antibodies in seropositive mice interfered with
the receptor-mediated uptake of rhGAA by the heart (fig.
3). LAMP-2, a marker for lysosomal accumulation, was
reduced in the heart for the majority of seronegative and
naive GAA-KO mice at 3 wk after rhGAA (100 mg/kg);
however, seropositive GAA-KO mice had persistently el-
evated LAMP-2 consistent with a lack of efficacy of a single
high dose of rhGAA treatment (fig. 3). These data indicate
that the presence of anti-hGAA antibodies severely im-
pacted the efficacy of ERT, whereas immune tolerance
through gene therapy greatly improved the efficacy of
ERT.
The impact of immune tolerance on long-term ERT was
evaluated by comparison of the efficacy in vector-treated
and mock-treated GAA-KO mice. ERT was administered
every other week for 12 wk, starting at age 4.5 mo, at doses
of 20 mg/kg, consistent with recommended clinical dos-
ages.7 Mock-treated GAA-KO mice died within hours after
the second or third dose of rhGAA, which is consistent
with anaphylaxis (fig. 4A), as was reported for nontolerant
GAA-KO mice.5 Endurance was significantly improved for
the 10.5-mo-old vector-treated GAA-KO mice after 12 wk
of sustained ERT, in comparison with vector-treated GAA-
KO mice that received no ERT (fig. 4B). Taken together,
these data indicate efficacy of ERT only in GAA-KO mice
rendered immunotolerant to rhGAA through gene ther-
apy. The possibility that low-dose vector–treated mice pro-
duce secreted hGAA was evaluated by enzyme analysis of
plasma, which revealed no elevation of plasma activity
either after ERT or with no ERT (fig. 4C); consistent with
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Figure 2. End points and biochemical correction depending on
antibody status after administration of rhGAA (100 mg/kg). Mean
 SD P values were calculated with Kruskal-Wallis and Dunn’s
multiple comparison tests and were considered significant if P !
(indicated by an asterisk [*]). A, Rotarod testing. The Rotarod.05
time was evaluated 2 wk after administration of rhGAA. Prior to
rhGAA administration (100 mg/kg) at age 10 mo, 3-mo-old GAA-
KO mice were administered the AAV vector, followed by immune
challenge with rhGAA  Freund’s adjuvant (“Seronegative”: np
; at 2 wk), or PBS followed by rhGAA  Freund’s adjuvant6 np 4
(“Seropositive”: ; at 2 wk). Naive GAA-KO mice re-np 7 np 6
ceived no prior treatment, before rhGAA administration (100 mg/
kg) at age 10 mo (“naive”: ; at 2 wk). Mice unavailablenp 5 np 4
for repeat testing at 2 wk after rhGAA administration died 124 h
after rhGAA injection, and these deaths were attributed to Pompe
disease. B, Tissue GAA assayed for GAA-KO mice 3 wk after ad-
ministration of rhGAA. C, Glycogen content in tissues for mice in
panel B.
Figure 3. Western blot detection of hGAA in cardiac muscle after
administration of rhGAA (100 mg/kg). Cardiac muscle was analyzed
3 wk after administration of rhGAA. Three different proteins were
detected, hGAA, LAMP-2, and b-actin. b-actin served as a control
to indicate equal loading of each lane. Samples were from GAA-
KO mice; either untreated, or rhGAA-treated seropositive, sero-
negative, and naive mice, for each group; and from C57BL/np 4
6 wild-type controls ( ). Each lane represents an individualnp 2
mouse.
this hypothesis, efficacy was associated with ERT, not with
gene therapy alone.
The efficacy of 12-wk sustained ERT was further eval-
uated in vector-treated GAA-KO mice through biochem-
ical correction of GAA deficiency and glycogen accumu-
lations (fig. 5), which should be corrected to prevent the
cardiorespiratory failure associated with this disorder.2 In
contrast to a single infusion of high-dose rhGAA, sus-
tained ERT increased the GAA activity significantly in vec-
tor-treated GAA-KO mice at 2 wk after the last injection
of rhGAA, in comparison with mock-treated GAA-KO mice
(fig. 5A). The correction of glycogen content in the heart
previously predicted efficacy in GAA-KO mice.15,28 Gly-
cogen content was reduced significantly only in the heart
of vector-treated mice after ERT, in comparison with that
of mock-treated GAA-KO mice, although the difference
between the glycogen contents of the diaphragm in these
groups also approached signficance ( ) (fig. 5B).Pp .055
Glycogen vacuolation was markedly reduced in the heart
and diaphragm after ERT in vector-treated mice (fig. 6).
The quadriceps were not biochemically corrected (fig. 5),
which is consistent with the need for higher doses of
rhGAA to accomplish clearance of glycogen from the skel-
etal muscle of GAA-KO mice compared with patients with
Pompe disease.7,30 Thus, AAV2/8 vector pretreatment me-
diated the clearance of stored glycogen from the heart and
diaphragm after ERT.
Discussion
These studies show that immune tolerance to rhGAA was
achieved for 118 wk in adult, immunocompetent GAA-
KO mice, through a single administration of a subthera-
peutic number of AAV vector particles encoding liver-
specific hGAA. The immune tolerance in vector-treated
GAA-KO mice was in marked contrast to mock-treated
Pompe disease mice that mounted an antibody response
against rhGAA, which reduced the efficacy of subsequent
ERT. Immune tolerance was demonstrated through an im-
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Figure 4. End points after ERT. Mean  SD P values were cal-
culated with Kruskal-Wallis and Dunn’s multiple comparison tests
and were considered significant if (indicated by an asteriskP ! .05
[*]). A, Proportion of mice surviving in each group at the indicated
age. B, Rotarod testing. Rotarod time was evaluated at age 7.5
mo. Mice were administered the AAV vector, followed by ERT
( ), no ERT ( ), or PBS without ERT ( ). P valuesnp 5 np 4 np 5
were calculated with a two-tailed homoscedastic Student’s t test.
C, Plasma GAA activity after hGAA  Freund’s adjuvant challenge
or ERT for mice in panel B.
Figure 5. Biochemical correction after ERT. Mean SD is shown.
P values were calculated with Kruskal-Wallis and Dunn’s multiple
comparison tests and were considered significant if (in-P ! .05
dicated by an asterisk [*]). Mice were administered the AAV vector,
followed by ERT ( ), no ERT ( ), or PBS without ERTnp 5 np 4
( ). A, Tissue GAA assayed for GAA-KO mice 18 wk after ad-np 5
ministration of the AAV vector or PBS. B, Glycogen content in
tissues for mice in panel A.
mune challenge with rhGAA, during which only vector-
treated Pompe disease mice failed to produce interfering
antibodies and demonstrated efficacious responses to ERT.
The relevance of pre-existing antibodies against hGAA was
confirmed by the lack of efficacy of high-dose rhGAA in
seropositive Pompe disease mice. These results support the
findings that ERT had little or no efficacy in CRIM-neg-
ative patients with Pompe disease after introduction of
rhGAA and subsequent antibody formation, as reported
during clinical trials of ERT.6,7,9
The complete lack of efficacy of ERT for Pompe disease
mice, which have complete deletion of exon 6 in the mu-
rine Gaa gene, might have a more severe outcome than
that for CRIM-negative patients with Pompe disease. In-
deed, most GAA-KO mice died after the second or third
dose of rhGAA here and in previous studies,5 although
pretreatment with clemastinum prolonged the survival of
another strain of GAA-KO mice over a 6-mo duration of
ERT.4 The generation of transgenic, liver-expressing, im-
munotolerant GAA-KO mice also facilitated long-term ERT
in a Pompe mouse.5 During the initial phase I/II clinical
trial and subsequent trials, CRIM-negative subjects with
Pompe disease produced very high levels of anti-hGAA
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Figure 6. Glycogen staining. Periodic acid-Schiff staining to vi-
sualize glycogen in striated muscle of GAA-KO mice. Arrows in-
dicate corrected myofibers (blackened arrowheads) or foci of gly-
cogen vacuolation (unblackened heads). Original magnificationp
200#.
antibodies and demonstrated markedly reduced efficacy
of ERT.6 The interfering antibody response in GAA-KO
mice and in CRIM-negative patients with Pompe disease
indicated that GAA deficiency stemming from an under-
lying null mutation(s) will not respond efficaciously in
the long-term to ERT.
The need for immunomodulation in CRIM-negative pa-
tients with Pompe disease follows from the lack of efficacy
of ERT. Similar immunological complications have been
encountered in hemophilia B mutations and animal mod-
els, which have been addressed in preclinical studies by
administration of immunosuppression with cyclophos-
phamide.31 Attempts to induce tolerance by this method
after high-titer anti-GAA antibodies developed in CRIM-
negative patients with Pompe disease were not successful.6
An alternative strategy, which avoids the risks of immu-
nosuppression, is provided by AAV vector–mediated in-
duction of immune tolerance. AAV vectors have been pro-
moted for gene therapy in genetic disease because of a
lack of toxicity and demonstrated long-term transgene ex-
pression.32 However, antibody production has prevented
long-term efficacy with AAV vectors in early experiments
that used GAA-KO mice.13,28,29 We previously found that
administration of an AAV2/8 vector containing a liver-
specific promoter evaded the humoral response to hGAA
and achieved near-total clearance of accumulated glyco-
gen from skeletal muscle, through the induction of im-
mune tolerance to hGAA.14 A dose-response experiment
revealed elevated GAA activity in plasma for 12 wk after
administration of as few as particles of the vector103# 10
containing a liver-specific promoter,15 which was validated
by demonstrating the efficacy of subsequent ERT here. The
persistent correction of hGAA deficiency and lack of anti-
hGAA antibodies over 18 wk were consistent with im-
mune tolerance to hGAA after administration of a low
dose of the AAV vector, which was within the range of
doses safely administered in a clinical trial of an AAV vec-
tor in patients with hemophilia B.33,34 The low risk of gen-
otoxic effects from chromosomal integration, which are
very infrequent with AAV vectors, would be reduced fur-
ther by administration of a low number of vector par-
ticles.32,35 Finally, it is possible that the AAV vector need
not persist for the lifetime of the subject with Pompe dis-
ease, once immune tolerance and efficacy of ERT are es-
tablished. If so, the obstacles to readministration may be
overcome with the current strategy.36–38
The current AAV2/8 vector appeared to induce tolerance
to hGAA when it was administered in higher particle num-
bers in GAA-KO mice, on the basis of lack of ELISA and
ELISpot responses against hGAA. By contrast, use of a
ubiquitously active cytomegalovirus enhancer–chicken b-
actin promoter provoked both humoral and cellular im-
mune responses by use of the same assays.14 AAV vectors
containing this liver-specific promoter also prevented an
antibody response against coagulation factor IX (FIX) in
hemophilia B mice and dogs.19,39 Several factors determine
the ability to avoid antibody responses against foreign pro-
tein by liver-specific expression. Higher levels of FIX were
associated with the induction of tolerance to liver-specific
FIX expression.16 Acquisition of tolerance to FIX required
the induction of regulatory CD4 T cells, most likely
CD25/CD4 T-regulatory cells, which suppressed neu-
tralizing antibody formation.16 Similarly, a liver-specific
promoter induced tolerance to a-galactosidase in Fabry
disease mice, and the transfer of splenocytes from vector-
treated mice prevented the antibody response against an
a-galactosidase challenge in recipient Fabry mice.21 Taken
together, these data strongly support the ability of an AAV
vector containing a liver-specific promoter to induce im-
mune tolerance to an introduced foreign protein. Here,
we show that this phenomenon can be exploited to
achieve efficacy of ERT in the otherwise immunocompe-
tent GAA-KO mouse.
The proposed strategy for immunomodulatory gene
therapy would be attractive because a low dose of a non-
toxic viral vector might induce immunotolerance to ERT
in patients who are likely to have a poor response to ERT
because of immune responses against hGAA. The alter-
native strategy, immune suppression to prevent antibody
formation, has potentially severe side effects, such as bone
marrow suppression, secondary infections, and malig-
nancy. Immunomodulatory gene therapy with the ap-
proach described here may be relevant to therapy for other
disorders that are complicated by immune responses, in-
cluding treatment of other lysosomal storage disorders
and the hemophilias.
Further preclinical studies of immunomodulatory gene
therapy are clearly indicated in immunocompetent
Pompe disease mice and Japanese quail.3,27 The immuno-
modulatory approach to gene therapy in Pompe disease
has special relevance, because ∼40% of patients with in-
fantile Pompe disease are CRIM negative, including the
majority of African American patients.6,7,9 These CRIM-
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negative subjects would not be expected to respond to ERT
once antibodies develop. Therefore, infants with Pompe
disease should be screened for CRIM status before initia-
tion of ERT, and CRIM-negative patients should be eligible
for a clinical trial of immunomodulatory, AAV vector–
mediated gene therapy. Indeed, this subpopulation of sub-
jects with Pompe disease represents an important unmet
need for therapy, despite the recent approval of rhGAA.
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